Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Warfarin traps human vitamin K epoxide reductase in an intermediate state during electron transfer

Journal Article · · Nature Structural & Molecular Biology
DOI:https://doi.org/10.1038/nsmb.3333· OSTI ID:1463095
 [1];  [2];  [2];  [3];  [4];  [5];  [3];  [3];  [3];  [6];  [2];  [3]
  1. Henan Univ. of Science and Technology, Luoyang (China). College of Medicine; Amgen Inc., Cambridge, MA (United States); Washington Univ., St. Louis, MO (United States). School of Medicine and Dept. of Biochemistry and Molecular Biophysics; OSTI
  2. Washington Univ., St. Louis, MO (United States). Dept. of Chemistry
  3. Washington Univ., St. Louis, MO (United States). School of Medicine and Dept. of Biochemistry and Molecular Biophysics
  4. Washington Univ., St. Louis, MO (United States). School of Medicine and Dept. of Biochemistry and Molecular Biophysics; Shanghai Jiao Tong Univ. (China). School of Chemistry and Chemical Engineering
  5. Washington Univ., St. Louis, MO (United States). School of Medicine and Dept. of Biochemistry and Molecular Biophysics; Huazhong Univ. of Science and Technology, Wuhan (China). Tongji Medical College and Dept. of Forensic Medicine
  6. Washington Univ., St. Louis, MO (United States). School of Medicine and Division of Hematology

Although warfarin is the most widely used anticoagulant worldwide, the mechanism by which warfarin inhibits its target, human vitamin K epoxide reductase (hVKOR), remains unclear. We show that warfarin blocks a dynamic electron-transfer process in hVKOR. A major fraction of cellular hVKOR is at an intermediate redox state of this process containing a Cys51-Cys132 disulfide, a characteristic accommodated by a four-transmembrane-helix structure of hVKOR. Warfarin selectively inhibits this major cellular form of hVKOR, whereas disruption of the Cys51-Cys132 disulfide impairs warfarin binding and causes warfarin resistance. Relying on binding interactions identified by cysteine alkylation footprinting and mass spectrometry coupled with mutagenesis analysis, we are able to conduct structure simulations to reveal a closed warfarin-binding pocket stabilized by the Cys51-Cys132 linkage. Understanding the selective warfarin inhibition of a specific redox state of hVKOR should enable the rational design of drugs that exploit the redox chemistry and associated conformational changes in hVKOR.

Research Organization:
Washington Univ., St. Louis, MO (United States)
Sponsoring Organization:
USDOE; China Scholarship Council (CSC); Burroughs Wellcome Fund (BWF); National Inst. of Health (NIH); American Heart Association (AHA); American Society of Hematology (ASH)
Contributing Organization:
Univ. of North Carolina, Chapel Hill, NC (United States); Umeå Univ. (Sweden)
Grant/Contract Number:
SC0001035
OSTI ID:
1463095
Journal Information:
Nature Structural & Molecular Biology, Journal Name: Nature Structural & Molecular Biology Journal Issue: 1 Vol. 24; ISSN 1545-9993
Publisher:
Nature Publishing GroupCopyright Statement
Country of Publication:
United States
Language:
English

References (53)

GROMACS: Fast, flexible, and free journal January 2005
Solubilization and characterization of vitamin K epoxide reductase from normal and warfarin-resistant rat liver microsomes journal February 1984
Is thioredoxin the physiological vitamin K epoxide reducing agent? journal July 1992
Vitamin K1 hydroquinone formation catalyzed by a microsomal reductase system journal December 1980
Reduced thioredoxin: A possible physiological cofactor for vitamin k epoxide reductase. further support for an active site disulfide journal September 1988
R- and S-Warfarin inhibition of vitamin K and vitamin K 2,3-epoxide reductase activities in the rat. journal May 1982
The Vitamin K Cycle book January 2008
Structure and Function of Vitamin K Epoxide Reductase book January 2008
Vitamin K‐Dependent Carboxylation book January 2008
Vitamin K and Bone Health in Adult Humans book January 2008
Biochemical characterization of spontaneous mutants of rat VKORC1 involved in the resistance to antivitamin K anticoagulants journal November 2011
Determination of the warfarin inhibition constant Ki for vitamin K 2,3-epoxide reductase complex subunit-1 (VKORC1) using an in vitro DTT-driven assay journal August 2013
Membrane topology of transmembrane proteins: determinants and experimental tools journal October 2014
Vitamin K epoxide reductase: homology, active site and catalytic mechanism journal June 2004
Warfarin inhibition of vitamin K 2,3-epoxide reductase in rat liver microsomes journal November 1983
Vitamin K dependent carboxylase: subcellular location of the carboxylase and enzymes involved in Vitamin K metabolism in rat liver journal March 1980
Interactions of Apurinic/Apyrimidinic Endonuclease with a Redox Inhibitor: Evidence for an Alternate Conformation of the Enzyme journal January 2011
The Conversion of Vitamin K Epoxide to Vitamin K Quinone and Vitamin K Quinone to Vitamin K Hydroquinone Uses the Same Active Site Cysteines journal June 2007
Model studies for a molecular mechanism of action of oral anticoagulants journal July 1981
Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2 journal February 2004
Identification of the gene for vitamin K epoxide reductase journal February 2004
Structure of a bacterial homologue of vitamin K epoxide reductase journal January 2010
The contribution of bone to whole-organism physiology journal January 2012
Structures of an intramembrane vitamin K epoxide reductase homolog reveal control mechanisms for electron transfer journal January 2014
False discovery rate estimation for cross-linked peptides identified by mass spectrometry journal July 2012
In-gel digestion for mass spectrometric characterization of proteins and proteomes journal December 2006
I-TASSER: a unified platform for automated protein structure and function prediction journal March 2010
Membrane-protein topology journal December 2006
Formation and transfer of disulphide bonds in living cells journal November 2002
The membrane topology of vitamin K epoxide reductase is conserved between human isoforms and the bacterial enzyme journal March 2016
Stimulation of the dithiol-dependent reductases in the vitamin K cycle by the thioredoxin system. Strong synergistic effects with protein disulphide-isomerase journal January 1992
Effect of VKORC1 Haplotypes on Transcriptional Regulation and Warfarin Dose journal June 2005
Purified vitamin K epoxide reductase alone is sufficient for conversion of vitamin K epoxide to vitamin K and vitamin K to vitamin KH2 journal December 2006
Vitamin K epoxide reductase prefers ER membrane-anchored thioredoxin-like redox partners journal August 2010
Novel Insight into the Mechanism of the Vitamin K Oxidoreductase (VKOR): ELECTRON RELAY THROUGH Cys journal October 2010
Human Vitamin K Epoxide Reductase and Its Bacterial Homologue Have Different Membrane Topologies and Reaction Mechanisms journal August 2012
Conserved Loop Cysteines of Vitamin K Epoxide Reductase Complex Subunit 1-like 1 (VKORC1L1) Are Involved in Its Active Site Regeneration journal February 2014
Membrane Topology Mapping of Vitamin K Epoxide Reductase by in Vitro Translation/Cotranslocation journal February 2005
Analysis of the Membrane Topology of Transmembrane Segments in the C-terminal Hydrophobic Domain of the Yeast Vacuolar ATPase Subunit a (Vph1p) by Chemical Modification journal May 2008
Expression of catalytic mutants of the mtDNA helicase Twinkle and polymerase POLG causes distinct replication stalling phenotypes journal April 2007
SwissDock, a protein-small molecule docking web service based on EADock DSS journal May 2011
Warfarin: almost 60 years old and still causing problems journal November 2006
Non-invasive topology analysis of membrane proteins in the secretory pathway journal February 2009
Thirteen novel VKORC1 mutations associated with oral anticoagulant resistance: insights into improved patient diagnosis and treatment: New VKORC1 mutations journal January 2011
A new cell culture-based assay quantifies vitamin K 2,3-epoxide reductase complex subunit 1 function and reveals warfarin resistance phenotypes not shown by the dithiothreitol-driven VKOR assay journal May 2013
Evaluation of warfarin resistance using transcription activator-like effector nucleases-mediated vitamin K epoxide reductase knockout HEK293 cells journal August 2013
Phycobilisomes Supply Excitations to Both Photosystems in a Megacomplex in Cyanobacteria journal November 2013
Human Herpesvirus 8 Viral Interleukin-6 Interacts with Splice Variant 2 of Vitamin K Epoxide Reductase Complex Subunit 1 journal November 2011
Membrane Topology and Insertion of Membrane Proteins: Search for Topogenic Signals journal March 2000
Human VKORC1 mutations cause variable degrees of 4-hydroxycoumarin resistance and affect putative warfarin binding interfaces journal October 2013
Novel mutations in the VKORC1 gene of wild rats and mice – a response to 50 years of selection pressure by warfarin? journal February 2009
Protein disulphide isomerase family members show distinct substrate specificity: P5 is targeted to BiP client proteins journal November 2009
The Genetic Basis of Resistance to Anticoagulants in Rodents journal May 2005

Cited By (4)

Genetic variation in human drug-related genes posted_content June 2017
Structural Insights into Phylloquinone (Vitamin K1), Menaquinone (MK4, MK7), and Menadione (Vitamin K3) Binding to VKORC1 journal January 2019
Warfarin and vitamin K epoxide reductase: a molecular accounting for observed inhibition journal August 2018
Genetic variation in human drug-related genes journal December 2017

Similar Records

Structure of a bacterial homologue of vitamin K epoxide reductase
Journal Article · Fri Mar 19 00:00:00 EDT 2010 · Nature · OSTI ID:1002272

Structural basis of antagonizing the vitamin K catalytic cycle for anticoagulation
Journal Article · Wed Nov 04 23:00:00 EST 2020 · Science · OSTI ID:1755274

Hepatic uptake and storage of warfarin. The relation with the target enzyme vitamin K 2,3-epoxide reductase
Journal Article · Mon Nov 30 23:00:00 EST 1987 · J. Pharmacol. Exp. Ther.; (United States) · OSTI ID:5362811